CTOs on the Move

Tizona Therapeutics

www.tizonatx.com

 
Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies. Tizona Therapeutics, Inc. was founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women`s Hospital.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.tizonatx.com
  • 601 Gateway Blvd Suite 350
    South San Fransico, CA USA 94080
  • Phone: 650.383.0800

Executives

Name Title Contact Details

Funding

Tizona Therapeutics raised $43M on 03/08/2016
Tizona Therapeutics raised $300M on 07/21/2020

Similar Companies

Virsys

Virsys is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adma Biologics

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and com...

R I Analytical Laboratories Inc

R I Analytical Laboratories Inc is a Warwick, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Allakos

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company`s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis.

Trinity Biomedical

Trinity Biomedical is a Menomonee Falls, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.